Volume 1.00 | Jan 12

Hematopoiesis News 1.00, January 12, 2010.
In this issue: Science News  |   Current Publications  |   Industry News  |   Policy News  |   Events Subscribe   |  Unsubscribe


New Target Discovered for Treatment of Cancer
Researchers at the Swedish medical university Karolinska Institutet have discovered a new way of blocking the formation of blood vessels and halting the growth of tumors in mice. [Karolinska Institutet, Stockholm]

The most published medium for hematopoietic CFC assays

by STEMCELL Technologies


Scientists Find New Leukemia Gene Risk Factors
Researchers have found four new genetic variants that increase the risk of contracting one of the major forms of leukemia, confirming that risk factors for the fatal blood cancer can be inherited. [The European Association for Cancer Research, Nottingham]

Leukemia Vaccine Being Developed
A vaccine treatment for Leukemia can be used to stop the disease returning after chemotherapy or bone marrow transplant. [King’s College London, London]

Johns Hopkins Researchers Say Vaccine Appears to “Mop Up” Leukemia Cells Gleevec Leaves Behind
Preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia patients taking the drug Imatinib mesylate (Gleevec). [Johns Hopkins University, Baltimore]

China Surpasses Canada in Stem Cell Advances
Scientists in China, many of them trained at North American and European universities, published 1,116 articles on stem cells in international peer-reviewed journals in 2008, up from just 37 papers in 2000, says a team at the University of Toronto documenting China’s aggressive bid to become a major player in regenerative medicine. [University of Toronto, Toronto]



W41/W41 Blastocyst Complementation: A System for Genetic Modeling of Hematopoiesis
This study reports a rapid and highly efficient approach to generate mice in which the hematopoietic system is derived from embryonic stem cells. [Blood]

Loss-Of-Function Additional Sex C ombs Like 1 Mutations Disrupt Hematopoiesis But Do Not Cause Severe Myelodysplasia or Leukemia
The Additional sex combs like 1 ( Asxl1 ) knockout mice exhibit defects in frequency of differentiation of lymphoid and myeloid progenitors, but not in multipotent progenitors. [Blood]

Human-Induced Pluripotent Stem Cells from Blood Cells of Healthy Donors and Patients with Acquired Blood Disorders
Human induced pluripotent stem cells were derived from postnatal human blood cells and the potential of these pluripotent cells for disease modeling was reported. [Blood]

Shedding of the Endothelial Receptor Tyrosine Kinase Tie2 Correlates with Leukemic Blast Burden and Outcome after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
The purpose of this study was to elucidate whether the soluble domain of the Tie2 receptor predicts outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. [Ann Hematol]

Transforming Growth-Interacting Factor Regulates Proliferation and Differentiation of Human Myeloid Leukemia Cells
Transforming Growth-Interacting Factor has an important role in myelopoiesis and may regulate the balance between proliferation and differentiation. [Mol Oncol]

Occupational Exposure to Formaldehyde, Hematotoxicity, and Leukemia-Specific Chromosome Changes in Cultured Myeloid Progenitor Cells
Results suggest that formaldehyde exposure can have an adverse effect on the hematopoietic system and that leukemia induction by formaldehyde is biologically plausible, which heightens concerns about its leukemogenic potential from occupational and environmental exposures. [Cancer Epidemiol Biomarkers Prev]

The Toll-Like Receptor 7/8 Agonist Resiquimod Greatly Increases the Immunostimulatory Capacity of Human Acute Myeloid Leukemia Cells
The immunostimulatory effect of the Toll-like receptor (TLR) 7/8 agonist R-848 on human acute myeloid leukemia cells could prove useful for the design of TLR-based immunotherapy for leukemia. [Cancer Immunol Immunother]

Request A Sample  
Column-Free Isolation of
Hematopoietic Stem and Progenitor Cells
with EasySep®


Amgen Shares Dip On Anemia Drug Concerns
Shares of Amgen Inc. fell on concerns that the Food and Drug Administration’s plans to re-examine the safety of anemia drugs, which could put more pressure on sales of leading anemia treatments Aranesp and Epogen.

AMAG Shares Rise on Strong Revenue Outlook for Anemia Drug
Shares of AMAG Pharmaceuticals Inc. rose as much as 16 percent after the biop harmaceutical company provided a strong fourth-quarter revenue outlook for its injectable anemia medicine Feraheme.

Cyclacel to Raise Up to $9.5 Million in Registered Direct Offering
Cyclacel Pharmaceuticals, Inc. announced that it has entered into definitive agreements to raise $7.2 million in gross proceeds, before deducting placement agent fees and other estimated offering expenses, and up to an additional $2.3 million, in a registered direct offering with select institutional investors.

Ablynx Successfully Generates Nanobodies Against an Ion Channel and Announces New GPCR Program
Ablynx announced two significant advances achieved within its R&D portfolio. In the first, it has demonstrated the successful generation of functional Nanobodies against an ion channel. In the second, Ablynx has demonstrated in vivo proof-of-concept for a G protein-coupled receptor targeting stem cell mobilization program.

Aryx Gets FDA Guidance on Blood Clot Drug that Failed Trial
Aryx Therapeutics Inc. got guidance from the Food and Drug Administration on the continued development of tecarfarin, an anticoagulant that failed a clinical trial last year.


Erythropoiesis-Stimulating Agents – Time for a Reevaluation [Food and Drug Administration, United States]

Notice on P40 Page Limits (NOT-RR-10-002) [National Institutes of Health, United States]

Academic Research Enhancement Award (Parent R15) (PA-10-070) [National Institutes of Health, United States]

NIH Broadens Eligibility for NIH Diversity and Re-Entry Supplements (NOT-OD-10-045) [National Institutes of Health, United States]

Salary Limitation on FY2010 AHRQ Grants, Cooperative Agreements, and Contracts
[Agency for Healthcare Research and Quality, United States]

Technologies and Software to Support Integrative Cancer Biology Research (R43/R44) [Small Business Innovation Research, United States]

Complete List of Licensed Products and Establishments [Center for Biologics Evaluation and Research, United States]


2010 Bone Marrow Transplant Tandem Meetings
February 24-28, 2010
Orlando, United States

36th Annual Meeting of the European Group for Blood & Marrow Transplantation
March 21-24, 2010
Vienna, Austria

12th Biennial CBMTG Conference< BR>April 7-10, 2010
Vancouver, Canada

ISSCR 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

XXXIst International Congress of the ISBT in joint cooperation with the 43rd Congress of the DGTI
June 26-July 1, 2010
Berlin, Germany

36th Annual Meeting of the American Society for Histocompatibility & Immunogenetics
September 26-30, 2010
Hollywood, United States

AABB Annual Meeting & TXPO 2010
October 9-12, 2010
Baltimore, United States

52nd ASH Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy comm unity.


Research & Development Scientist – Pancreatic Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Endothelial Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Epithelial Cell Biology (STEMCELL Technologies)

Data Entry Assistant – Marketing (STEMCELL Technologies)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!


Learn more about Hematopoiesis News: Archives  |   Events  |   Subscribe  |   Contact Us